Ubi Pharma Inc

UBI Pharma Inc, established on July 31, 2014, is a trailblazing force in the pharmaceutical industry. We take pride in being the first pharmaceutical company in Asia (excluding Japan) to successfully pass the rigorous US FDA inspection for our injection filling production line. With over two decades of experience in the pharmaceutical sector, we have forged a path dedicated to pioneering long-acting protein drugs and specialized injectables. At UBI Pharma Inc, we boast several patented technology platforms, including the Specialty Injectable Development Platform (peptide & lyophilized formulation), Multicomponent Tablet Formulation Technology Platform, Long-Acting Small Molecule Drug Technology Platform, and Long-Acting Protein Drug Development Technology. In 2018, we introduced the International Contract Development and Manufacturing (CDMO) one-stop service business model, complementing our original Contract Manufacturing service (CMO). Our exceptional team spans the spectrum of protein and specialty injectable drug development, mass production technology, clinical expertise, regulatory affairs, and pharmaceutical manufacturing management. With a focus on Europe, America, Japan, and beyond, we are determined to disseminate our services and products worldwide, thereby making significant contributions to the dynamic fields of biotechnology and pharmaceuticals.